首页> 美国卫生研究院文献>PLoS Clinical Trials >Possible clinical effects of molecular hydrogen (H2) delivery during hemodialysis in chronic dialysis patients: Interim analysis in a 12 month observation
【2h】

Possible clinical effects of molecular hydrogen (H2) delivery during hemodialysis in chronic dialysis patients: Interim analysis in a 12 month observation

机译:慢性透析患者血液透析期间分子氢(H2)输送的可能临床效果:12个月观察中的中期分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background and aimIt is supposed that enhanced oxidative stress and inflammation are involved with the poor clinical outcomes in patients on chronic dialysis treatment. Recent studies have shown that molecular hydrogen (H2) is biologically active as an anti-inflammatory agent. Thus, we developed a novel hemodialysis (E-HD) system which delivers H2 (30 to 80 ppb)-enriched dialysis solution, to conduct a prospective observational study (UMIN000004857) in order to compare the long-term outcomes between E-HD and conventional-HD (C-HD) in Japan. The present interim analysis aimed to look at potential clinical effects of E-HD during the first 12 months observation.
机译:背景和目的据推测,慢性透析治疗患者的不良临床预后与氧化应激和炎症的增强有关。最近的研究表明,分子氢(H2)作为抗炎剂具有生物活性。因此,我们开发了一种新型血液透析(E-HD)系统,该系统可提供富含H2(30至80 ppb)的透析溶液,以进行前瞻性观察研究(UMIN000004857),以比较E-HD和日本的传统高清(C-HD)。本期中期分析旨在观察在最初12个月观察期间E-HD的潜在临床效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号